Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, colorectal 1

2620 - A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial


09 Oct 2016


Gastrointestinal tumours, colorectal 1


Derek Jonker


Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370


D.J. Jonker1, L. Nott2, T. Yoshino3, S. Gill4, J. Shapiro5, A. Ohtsu6, J. Zalcberg7, M.M. Vickers8, A. Wei9, Y. Gao10, N. Tebbutt11, B. Markman12, T. Esaki13, S. Koski14, M. Hitron10, N.M. Magoski15, J. Simes16, C. Li17, D. Tu18, C.J. O'Callaghan19

Author affiliations

  • 1 Department Of Medicine, Division Of Medical Oncology, Ottawa Hospital Research Institute, University of Ottawa, K1H8L6 - Ottawa/CA
  • 2 Medical Oncology, Royal Hobart Hospital, Hobart/AU
  • 3 Gastroenterology & Gastrointestinal Oncology, National Cancer Center Hospital East, 277-8577 - Chiba/JP
  • 4 Department Of Medicine, Vancouver General Hospital & HSC, British Columbia University, Vancouver/CA
  • 5 Department Of Medicine, Cabrini Hospital, Melbourne/AU
  • 6 Department Of Gastroenterology And Gastrointestinal Oncology, National Cancer Center East, 277-8577 - Kashiwa/JP
  • 7 School Of Public Health & Preventive Medicine, Monash University, Melbourne/AU
  • 8 Department Of Medicine, Division Of Medical Oncology, Ottawa Hospital Research Institute, University of Ottawa, Ottawa/CA
  • 9 Division Of General Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto/CA
  • 10 Clinical Development, Boston Biomedical Incorporated, Boston/US
  • 11 Medical Oncology, Austin Hospital, 3084 - Heidelberg/AU
  • 12 Monash Cancer Centre, Monash Health, 3165 - Melbourne/AU
  • 13 Gastrointestinal And Medical Oncology, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 14 Department Of Medicine, University of Alberta Cross Cancer Institute, Edmonton/CA
  • 15 Canadian Cancer Trials Group, Queens University, Kingston/CA
  • 16 Oncology, NHMRC Clinical Trials Centre, Sydney/AU
  • 17 Global Oncology, Boston Biomedical Incorporated, Boston/US
  • 18 Department Of Mathematics And Statistics, Canadian Cancer Trials Group, Queens University, Kingston/CA
  • 19 Department Of Public Health Sciences, Canadian Cancer Trials Group, Queens University, Kingston/CA


Abstract 2620


NAPA is a first-in-class cancer stemness inhibitor that targets STAT3, with promising activity in early trials.


Pts with ACRC who had failed all available standard therapy were randomized 1:1 to NAPA 480mg po q12h or PBO. Primary endpoint was overall survival (OS). Pre-specified biomarker analyses included pSTAT3 positivity by IHC in archival tissue based on nuclear staining of cancer cells >5% and stroma ≥2+. The study, designed to enrol 650 pts, was stopped after a futility analysis on disease control rate (DCR) in the first 96 pts. Analyses included Intent-to-treat (ITT) and exploratory Pre-defined Minimum Effective Treatment (pts who received ≥50% total daily dose for ≥6.4 weeks).


282 pts were randomized (138 NAPA, 144 PBO) from 04/2013 - 05/2014 when the trial was unblinded, accrual closed, and protocol treatment stopped after the futility analysis. Pts were median age = 64 (32 to 85); male = 65%; ECOG 0:1 (%) =28:72; >4 prior regimens = 98%; prior anti-VEGF = 89%; KRAS WT = 52%. No significant difference was observed in OS, progression free survival (PFS) or DCR between NAPA and PBO in the ITT analysis. AE more frequent with NAPA included: any grade diarrhea (88 vs 32%), nausea (63 vs 47%), and anorexia (56 vs 46%), all p 


In this trial, NAPA monotherapy did not improve OS or PFS in unselected ACRC. While pSTAT3 positivity was a poor prognostic factor in untreated pts, NAPA treatment in pts with positive pSTAT3 significantly improved OS.

Clinical trial identification


Legal entity responsible for the study

Canadian Cancer Trials Group (CCTG) at Queens University in Kingston, ON, Canada


Canadian Cancer Society Research Institute (CCSRI) with funding support from Boston Biomedical Inc.


D.J. Jonker: Co-investigator on trials sponsored by Boston Biomedical Incorporated. No direct or indirect financial or other gain. No personal conflict. L. Nott: No conflict of interest pertaining to this research. Member on advisory committees for Roche and MSD. T. Yoshino: No conflict of interest relevant to this research. Has received research funding from GlaxoSmithKline K.K., and Boehringer Ingelheim GmbH. J. Zalcberg: No relevant conflicts for this research. Research and Travel Support Bayer (Stivarga) M.M. Vickers: No relevant conflicts for this research. Advisory Boards for Ipsen, Celgene, Amgen. Y. Gao: Employee, Boston Biomedical Incorporated T. Esaki: Research Funding; Sumitomo Dainippon Pharma. M. Hitron, C. Li: Employee, Boston Biomedical Incorporated. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings